Skip to content

Annexon ANNX Enterprise value

Enterprise value at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$81.42B+18.1%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$3.82B+565%
Omeros logo
OmerosOMER
$1.22B+108%
Vor Biopharma logo
Vor BiopharmaVOR
$704.51M+902%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$787.38M+114%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$2.14B+874%

Other financials

Income statement

See full
Operating income-$46.1M+19.8%
Net income-$44.1M+18.8%
EPS (diluted)-$0.23+37.8%

Balance sheet

See full
Cash & equivalents$175.2M+80.4%
Total debt$25.4M-10.2%
Total equity$204.5M-16.1%
Total assets$262.9M-13.2%

Cash flow

See full
Operating cash flow-$46.8M+6.5%
CapEx--100%
Free cash flow-$46.8M+6.6%

Valuation

See full
Market cap$868.37M+233%

Returns & leverage

See full
Return on equity-87.6%+42.3pp
Debt / equity0.1×0.0×
Current ratio6.4×-1.6×

Where this comes from

Calculated from Annexon’s reported figures.

The official record: Annexon’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Annexon's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Annexon's enterprise value?
Annexon (ANNX) reported enterprise value of $676M in Q1 2026.
How has Annexon's enterprise value changed year-over-year?
Annexon's enterprise value increased by 373.0% year-over-year, from $142.93M to $676M.
What is the long-term trend for Annexon's enterprise value?
Over 4 years (2021 to 2025), Annexon's enterprise value has grown at a 11.2% compound annual growth rate (CAGR), from $400.67M to $612.41M.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.